Inflexion Private Equity Partners LLP (“Inflexion”) is delighted to announce that it has launched a Healthcare Advisory Board to help shape its investment strategy and drive value across healthcare investments, both in the UK and internationally.
The Board is comprised of:
- Dee Athwal, pharma and biotech adviser for over 15 years, CEO of Complement Therapeutics and previously held senior roles at Capella Bioscience and UCB
- John Beighton, Chair of Acino and Advanz and previously a board member at Zentiva and CEO of AMCo and Mercury Pharma
- Jan Egberts, Chair of Viroclinics, PhotoCure (PHO.OL), NordicNanovector (NANO.OL) and previously CEO of OctoPlus (OCTO), Agendia, Chair of Mölnlycke Healthcare and member of the Global Executive Board of J&J Medical
- Jane Griffiths, NXD at Johnson Matthey and BAE Systems, Chair of Redx Pharma, and former leadership roles at Janssen and Global Head of Actelion
- Steve Kent, Chair of Phlexglobal, 4ways and Pharmaspectra; former Chair of CRF Health; and a Board member at Parexel
- Rob Scott, formerly Chief Medical Officer and Head of Development at AbbVie, and held senior roles at Amgen and Pfizer
- Charles Woler, Chair at Sygnature Discovery, Chair or non-executive director at various life science businesses in Europe and US; former CEO of Roche France and CEO of Cadus Pharmaceuticals
Inflexion currently has a dedicated team of 11 professionals focused on healthcare investing in the UK and across Europe. It has a number of healthcare companies in its current portfolio including Rosemont Pharmaceuticals, CNX Therapeutics, Pharmaspectra and ELCG.
